JP2010510965A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510965A5
JP2010510965A5 JP2009535833A JP2009535833A JP2010510965A5 JP 2010510965 A5 JP2010510965 A5 JP 2010510965A5 JP 2009535833 A JP2009535833 A JP 2009535833A JP 2009535833 A JP2009535833 A JP 2009535833A JP 2010510965 A5 JP2010510965 A5 JP 2010510965A5
Authority
JP
Japan
Prior art keywords
reaction
seq
primer
dna
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009535833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510965A (ja
JP5584865B2 (ja
Filing date
Publication date
Priority claimed from FR0609749A external-priority patent/FR2908133B1/fr
Application filed filed Critical
Publication of JP2010510965A publication Critical patent/JP2010510965A/ja
Publication of JP2010510965A5 publication Critical patent/JP2010510965A5/ja
Application granted granted Critical
Publication of JP5584865B2 publication Critical patent/JP5584865B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009535833A 2006-11-08 2007-11-08 抗ウイルス薬のための前駆体分子としての新規なヌクレオチド類似体 Expired - Fee Related JP5584865B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0609749A FR2908133B1 (fr) 2006-11-08 2006-11-08 Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
FR06/09749 2006-11-08
PCT/IB2007/004233 WO2008056264A2 (en) 2006-11-08 2007-11-08 Novel nucleotide analogues as percursor molecules for antivirals

Publications (3)

Publication Number Publication Date
JP2010510965A JP2010510965A (ja) 2010-04-08
JP2010510965A5 true JP2010510965A5 (https=) 2010-09-09
JP5584865B2 JP5584865B2 (ja) 2014-09-10

Family

ID=38018742

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535833A Expired - Fee Related JP5584865B2 (ja) 2006-11-08 2007-11-08 抗ウイルス薬のための前駆体分子としての新規なヌクレオチド類似体

Country Status (6)

Country Link
US (1) US8884011B2 (https=)
EP (1) EP2086990A2 (https=)
JP (1) JP5584865B2 (https=)
CA (1) CA2669450C (https=)
FR (1) FR2908133B1 (https=)
WO (1) WO2008056264A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2559788B1 (en) * 2010-04-16 2015-10-14 National University Corporation Okayama University Method for directly producing phosphine derivative from phosphine oxide derivative
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN104710424B (zh) * 2013-12-11 2017-03-01 河南师范大学 (r)‑(+)‑9‑(2‑羟丙基)腺嘌呤的制备方法
CN104725423A (zh) * 2013-12-18 2015-06-24 山东新时代药业有限公司 一种富马酸替诺福韦二吡呋酯的合成方法
CN105541910A (zh) * 2015-12-21 2016-05-04 山东金城医药化工股份有限公司 对甲苯磺酰氧甲基膦酸二乙酯的合成方法
CN107021985A (zh) * 2017-05-08 2017-08-08 四川理工学院 药物中间体r‑9‑[2‑(二乙氧基膦酰甲氧基)丙基]腺嘌呤的合成方法
WO2019120084A1 (zh) * 2017-12-21 2019-06-27 深圳市塔吉瑞生物医药有限公司 用于抗病毒的核苷类逆转录酶抑制剂
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US4935427A (en) * 1987-12-31 1990-06-19 The United States Of America As Represented By The Department Of Health And Human Services Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
US5072032A (en) * 1989-06-21 1991-12-10 Mckenna Charles E Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
CZ287745B6 (cs) 1991-10-11 2001-01-17 Ústav organické chemie a biochemie AV ČR Acyklické fosfonomethoxyalkylsubstituované alkenylové a alkinylové deriváty purinu a pyrimidinu
WO2003002580A1 (en) * 2001-06-29 2003-01-09 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
CN1523028A (zh) * 2003-02-18 2004-08-25 田镇华 一种新型的膦酸酯－核苷酸化合物
DE602004031115D1 (de) * 2003-06-16 2011-03-03 Acad Of Science Czech Republic Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
CN1634943A (zh) * 2004-11-05 2005-07-06 中国医学科学院医药生物技术研究所 一组非环核苷酸类似物及其合成方法和在抗病毒中的应用
WO2006114064A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry Ofthe Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物

Similar Documents

Publication Publication Date Title
JP2010510965A5 (https=)
TW567188B (en) A modified oligonucleotide, a method for amplifying a nucleic acid target sequence and a kit for carrying out a nucleic acid amplification reaction
Thi et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin
JP2022036182A (ja) Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子
Zheng et al. Progress and perspective of CRISPR‐Cas9 technology in translational medicine
Semenyuk et al. Synthesis of RNA using 2 ‘-O-DTM protection
JP2026016395A (ja) キャップアナログ及びその使用
WO2017181107A2 (en) Modified cpf1 mrna, modified guide rna, and uses thereof
Kore et al. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization
MXPA04007403A (es) Oligonucleotidos que comprenden segmentos alternos y usos de los mismos.
WO1995023162A1 (en) Modified oligonucleotide duplexes having anticancer activity
Blain et al. Synthesis and nonenzymatic template-directed polymerization of 2′-amino-2′-deoxythreose nucleotides
Earnshaw et al. Modified oligoribonucleotides as site‐specific probes of RNA structure and function
CN116875658B (zh) 一种脱氧核酶及检测mRNA加帽率的方法
Whetstine et al. The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element: basis for tissue-specific gene expression
EP4077667A1 (en) Use of sept9 inhibitors for treating hepatitis b virus infection
Knops et al. Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors
Kleiman et al. Incorporation of tRNA into normal and mutant HIV-1
Hou et al. Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes
WO2021122869A1 (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
Lanchy et al. Alternate usage of two dimerization initiation sites in HIV-2 viral RNA in vitro
Liao et al. Characterization of group I introns in generating circular RNAs as vaccines
Urata et al. Anti-HIV-1 activity and mode of action of mirror image oligodeoxynucleotide analogue of Zintevir
JP2026507087A (ja) ＲおよびＥを含む二本鎖ｓｉＲＮＡアナログおよびそのコンジュゲート
US12378573B2 (en) Asparaginase based selection system for heterologous protein expression in mammalian cells